URGN at a glance
UroGen Pharma Ltd. (URGN, SEC CIK 1668243) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 20, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding UroGen Pharma Ltd. (URGN) shares worth $412.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Schoenberg Mark on September 8, 2026 of 871 shares at $42.92 per share.
- In the last 90 days, URGN insiders reported 0 open-market purchases ($0) and 4 open-market sales ($3.4M) on Form 4, a net sale of $3.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $109.8M
- +21.4% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$3.4M
- 13F holders
- 27 funds
- $412.8M · +3 vs prior quarter
- Latest 8-K
- Aug 20, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability, net income, or actual margin percentages provided
- Best and worst product-line performance not disclosed with quarterly numbers
- UGN-103 NDA submission remains targeted for third quarter 2026, potential FDA approval in 2027
- UGN-104 enrollment expected complete by end of 2026; UGN-501 Phase 1 expected fourth quarter 2026
Risk Factors
- Accumulated deficit $997.6M as of June 30, 2026, with continuing losses threatening funding for operations and debt service
- Pharmakon facility expanded to $250.0M, with $200.0M drawn at 8.25% fixed interest and restrictive covenants
- New 2026 Loan Agreement triggered by February 26, 2026 refinancing, creating collateral and accelerated-default exposure
- Zusduri commercialization remains near-term execution risk after U.S. launch in June 2025 and limited marketing experience
- Available liquidity included $108.0M cash and securities plus approximately $42.4M remaining ATM capacity at June 30, 2026
AI summary of the URGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline
- SRGel platform targets sustained-release delivery, potentially complementing UroGen’s drug-delivery expertise
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 financial results announced
- Full results and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- ZUSDURI revenue reached $50.4M, up 73% quarter-over-quarter, signaling rapid launch adoption across 1,444 care sites
- Repeat prescribers rose to 45% from 40%, supporting improving retention and commercial durability
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved director and officer insurance changes within the compensation policy
- 2017 Equity Incentive Plan expanded by 1,000,000 ordinary shares
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven director nominees elected, preserving board continuity through the next annual meeting
- Amended and restated Articles of Association approved, changing the company’s governing framework
AI summaries of URGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for URGN
Don't miss the next URGN filing
- Alerts as it files. A push when URGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut URGN, by share count.
- Ask anything. An AI agent that reads every URGN filing and answers with sources.
URGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schoenberg Mark | Sell | Sep 8, 2026 | 871 | $42.92 |
| Smith Jason Drew | Sell | Sep 8, 2026 | 1,519 | $42.54 |
| Schoenberg Mark | M | Sep 7, 2026 | 1,667 | - |
| Schoenberg Mark | M | Sep 7, 2026 | 1,667 | - |
| Smith Jason Drew | M | Sep 7, 2026 | 3,334 | - |
| Smith Jason Drew | M | Sep 7, 2026 | 3,334 | - |
| Robinson James A. Jr. | M | Aug 26, 2026 | 2,000 | - |
| Robinson James A. Jr. | M | Aug 26, 2026 | 2,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $82.7M | $90.4M | $109.8M |
| Gross Profit | - | $81.5M | $97.3M |
| Operating Income | - | -$96.8M | -$124.9M |
| Net Income | - | -$126.9M | -$153.5M |
| Gross Margin | - | 90.2% | 88.7% |
| Op. Margin | - | -107.1% | -113.7% |
| Net Margin | - | -140.4% | -139.8% |
| Balance Sheet | |||
| Total Assets | - | $285.7M | $200.5M |
| Equity | - | -$8.8M | -$105.5M |
| ROE | - | 1441.3% | 145.5% |
| Per Share | |||
| EPS | - | $-2.96 | $-3.19 |
| Cash Flow | |||
| Operating CF | - | -$96.8M | -$162.4M |
| CapEx | $194K | $295K | $289K |
Source: XBRL data in UroGen Pharma Ltd. (URGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate URGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $412.8M |
| Q1 2026 | 24 | $185.0M |
| Q4 2025 | 25 | $274.2M |
| Q3 2025 | 24 | $260.5M |
| Q2 2025 | 25 | $143.7M |
| Q1 2025 | 18 | $49.8M |
| Q4 2024 | 15 | $33.2M |
| Q3 2024 | 14 | $45.2M |
- BlackRock+355.9K (+13%)
- Bank of America Corp+348.9K (+275%)
- Goldman Sachs Group+221.3K (+37%)
- State Street Corp+128.9K (+15%)
- D.E. Shaw & Co+122.7K (+12%)
- Millennium Management−264.2K (-71%)
- Citadel Advisors LLC−255.0K (-95%)
- Two Sigma Investments−28.9K (-16%)
- ARK Investment Management−14.0K (-12%)
- Invesco Ltd−2.2K (-8%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 172 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
URGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 8-K | Mar 2, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
URGN SEC filings: frequently asked questions
Are URGN insiders buying or selling?
In the last 90 days, UroGen Pharma Ltd. (URGN) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $3.4 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold URGN stock?
As of June 30, 2026, the largest UroGen Pharma Ltd. (URGN) holders among the 13F filers tracked by SignalX were BlackRock ($117.8 million), Morgan Stanley ($94.8 million), D.E. Shaw & Co ($42.2 million), State Street Corp ($36.9 million), Goldman Sachs Group ($30.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was URGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), UroGen Pharma Ltd. (URGN) reported revenue of $109.8 million (up 21.4% from FY2024) and a net loss of $153.5 million. Diluted EPS was -$3.19. The figures come from the XBRL data in the 10-K.
What did URGN report in its latest 8-K?
UroGen Pharma Ltd. (URGN) filed an 8-K on August 20, 2026 reporting Item 8.01 (Other Events). Exclusive worldwide option for TumoCure and additional SRGel-based products expands UroGen’s oncology pipeline.
What are the latest URGN SEC filings?
UroGen Pharma Ltd. (URGN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 20, 2026 and a Form 4 insider filing on September 9, 2026.
What is URGN's SEC CIK number?
UroGen Pharma Ltd. (URGN)'s SEC Central Index Key (CIK) is 1668243. EDGAR lists every URGN filing under that number.
Ask anything about URGN
The research agent reads URGN's filings, financials, insider trades and 13F holders, then answers with sources.